ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Show more

Location: 2000 Frontis Plaza Blvd., Winston-Salem, NC, 27103, United States | Website: https://prokidney.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.80B

52 Wk Range

$0.46 - $7.13

Previous Close

$2.36

Open

$2.38

Volume

1,122,407

Day Range

$2.25 - $2.38

Enterprise Value

30.3M

Cash

294.7M

Avg Qtr Burn

-28.61M

Insider Ownership

28.84%

Institutional Own.

30.46%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.